Treatment efficiency in patients with acute myeloid leukemia from 2019 to 2023 according to the Moscow Cancer Registry

Aim. To evaluate the acute myeloid leukemia (AML) treatment efficacy in adults in Moscow real clinical practice according to the Moscow Cancer Registry data.

Materials and methods. We retrospectively collected data from the Moscow Cancer Registry on Moscow permanent residents who were primary diagnosed with AML from January 2019 to November 2023. The effectiveness of antitumor therapy was assessed by the complete remissions rate, relapses, deaths, and 3-year overall and relapse-free survival. Data analysis performed as of 01.12.2023.

Results. According to the Moscow Cancer Registry, from 01.01.2019 to 01.12.2023, the diagnosis of AML (except for acute promyelocytic leukemia) was established in 752 patients with a median age at the time of diagnosis of 64 (19– 94) years. In the studied sample, females slightly predominated: women – 56.6 % (n = 426), men – 43.4 % (n = 326). Of all patients included in the study, 36 % (n = 275) received intensive chemotherapy, while 57 % (n = 427) received low-intensity chemotherapy, and the remaining 7 % (n = 50) patients received best supportive care. Early mortality (first 60 days) in the total group was 16 % (n = 123), 20 % (n = 149) of patients were refractory to the therapy. Complete remission was achieved by 63 % (n = 473) of patients: 82 % (n = 225) of them received intensive chemotherapy, 58 % (n = 248) – low-intensity chemotherapy. Relapses occurred in 41 % (n = 194) of 473 patients who achieved complete remission. In the first remission, allogeneic hematopoietic stem cell transplantation was performed in 11 % (n = 79) of patients. With a median follow-up of 30.1 months, the 3-year overall survival in total group was 27 % (95 % confidence interval 23–32), and the 3-year relapse-free survival was 44 % (95 % confidence interval 37–51).

Conclusion. The main problem in the treatment of adult AML patients remains high induction mortality and limited opportunities for allogeneic hematopoietic stem cell transplantation in real clinical practice, which emphasizes the need to develop transplant centers in Moscow.

1. Afanas’ev B.V., Baranova O.Yu., Bondarenko S.N. et al. Clinical guidelines “Acute myeloid leukemia”. Moscow: Ministry of Health of Russia, 2020. 87 p. Available at: https://cr.minzdrav.gov.ru/ recomend/131_1 (In Russ.).

2. Short N.J., Rytting M.E., Cortes J.E. Acute myeloid leukaemia. Lancet 2018;392(10147):593–606. DOI: 10.1016/S0140-6736(18)31041-9

3. Malignant tumors in Russia in 2020 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2021. 252 p. (In Russ.).

4. Semochkin S.V., Tolstykh T.N., Arkhipova N.V. et al. Clinical and epidemiological characteristics of acute myeloid leukemias in adults according to the data of municipal hematology departments in Moscow. Terapevticheskiy arkhiv = Therapeutic Archive 2015;87(7):26–32. (In Russ.). DOI: 10.17116/terarkh201587726-32

5. Döhner H., Wei A., Appelbaum F. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022;140(12):1345–77. DOI: 10.1182/blood.202201686

6. Parovichnikova E.N., Lukianova I.A., Troitskaya V.V. et al. Development of program therapy for patients with acute myeloid leukemia under the age of 60 years, based on the principles of differentiated effects. Terapevticheskiy arkhiv = Therapeutic Archive 2021;93(7):753–62. (In Russ.). DOI: 10.26442/00403660.2021.07.200946

7. Sasaki K., Ravandi F., Kadia M.P. et al. De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer 2021;127(12):2049–61. DOI: 10.1002/encr.33458

8. Mayer R.J., Davis R.B., Schiffer C.A. et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331(14):896–903. DOI: 10.1056/NEJM199410063311402

9. Kantarjian H. Acute myeloid leukemia – major progress over four decades and glimpses into the future. Am J Hematol 2016;91(1):131–45. DOI: 10.1002/ajh.24246

10. Othus M., Appelbaum F.R., Petersdorf S.H. et al. Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 2015;21(3): 559–64. DOI: 10.1016/j.bbmt.2014.10.025

11. Parovichnikova E.N., Loukianova I.A., Troitskaya V.V. et al. Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation. Terapevticheskiy arkhiv = Therapeutic Archive 2018;90(7):14–22. (In Russ.). DOI: 10.26442/terarkh201890714-22

12. Gritsaev S.V., Martinkevitch I.S., Kostroma I.I. et al. Results of treatment of patients aged 60 years or older with acute myeloid leukemia. Klinicheskaya onkogematologiya = Clinical Oncohematology 2012;5(4):355–60. (In Russ.).

13. Swerdlow S.H., Campo E., Pileri S.A. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127(20):2375–90. DOI: 10.1182/blood-2016-01-643569

14. Arber D.A., Orazi A., Hasserjian R. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127(20):2391–405. DOI: 10.1182/blood-2016-03-643544

15. Bennett J.M., Catovsky D., Daniel M.T. et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103(4):620–5. DOI: 10.7326/0003-4819-103-4-620

16. Döhner H., Estey E., Grimwade D. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129(4):424–48. DOI: 10.1182/blood-2016-08-733196

17. Lachowiez C.A., Long N., Saultz J. et al. Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia. Blood Adv 2023;7(9):1899–909. DOI: 10.1182/bloodadvances.2022009010

18. Shallis R.M., Wang R., Davidoff A. et al. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev 2019;36:70–87. DOI: 10.1016/j.blre.2019.04.005

19. Turbeville S., Francis K.M., Behm I. et al. Prevalence and incidence of acute myeloid leukemia may be higher than currently accepted estimates among the ≥65 year-old population in the United States. Blood 2014;124(21):958. DOI: 10.1182/blood.V124.21.958.958

20. Dong Y., Shi O., Zeng Q. et al. Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. Exp Hematol Oncol 2020;9:14. DOI: 10.1186/s40164-020-00170-6

21. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. DOI: 10.3322/caac.21590

22. Juliusson G., Antunovic P., Derolf A. et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009;113(18): 4179–87. DOI: 10.1182/blood-2008-07-172007

23. Lopez A., de la Rubia J., Martin G. et al. Recent improvements in outcome for elderly patients with de novo acute myeloblastic leukemia. Leuk Res 2001;25(8):685–92. DOI: 10.1016/s0145-2126(01)00006-6

24. DiNardo C.D., Pratz K., Pullarkat V. et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 2019;133(1):7–17. DOI: 10.1182/blood-2018-08-868752

25. de Botton S., Montesinos P., Schuh A.C. et al. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial. Blood 2023;141(2):156–67. DOI: 10.1182/blood.2021014901

26. Stone R.M., Mandrekar S.J., Sanford B.L. et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 2017;377:454–64. DOI: 10.1056/NEJMoa1614359

27. Wei A.H., Tiong I.S. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML. Blood 2017;130(23):2469–74. DOI: 10.1182/blood-2017-08-78406